ERBB2 and breast cancer: A standard systemic therapy for HER2-positive primary breast cancer is a combination of anti-HER2 therapy (e.g., trastuzumab or pertuzumab) and chemotherapy, which is associated with a higher response rate, as anti-HER2 therapy has significantly improved disease-free survival [4–6].